Provention Bio is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. At Provention Bio, we approach autoimmune disease differently than traditional pharma, with a clear focus on early interception. Before symptoms present, before irreversible damage is done to the bodies, minds, and lives of patients and families, and before it’s too late —this is where we operate. Our lead investigational product candidate is currently under review by the U.S. Food and Drug Administration (FDA) for the delay or prevention of clinical type 1 diabetes in at-risk individuals. Our pipeline includes additional clinical-stage product candidates for autoimmune diseases, including celiac disease and lupus. We have a vision to change the world by unleashing the full potential of lives otherwise burdened or cut short by autoimmune disease. It may seem daunting, but once we realize the potential of every moment we can protect—in every life we can change—the work we do at Provention Bio becomes more than just a job. It becomes a calling.
Provention Bio is an Equal Opportunity Employer.
We invite you to learn more at www.ProventionBio.com and connect by following us on LinkedIn and Twitter (@ProventionBio).
Provention Bio is an Equal Opportunity Employer.
We invite you to learn more at www.ProventionBio.com and connect by following us on LinkedIn and Twitter (@ProventionBio).
Location: United States, New Jersey, Red Bank
Employees: 51-200
Total raised: $28.4M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.06.2017 | - | $28.4M | - |
Mentions in press and media 34
| Date | Title | Description |
| 06.01.2023 | Provention Bio Announces the Grant of Inducement Awards | RED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. PRVB (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted sto... |
| 05.02.2022 | Provention Bio Announces the Grant of Inducement Award | RED BANK, N.J., Feb. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company gran... |
| 28.01.2022 | Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA | RED BANK, N.J., Jan. 27, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced its intent to resubm... |
| 21.01.2022 | Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE) | RED BANK, N.J., Jan. 20, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study ... |
| 07.01.2022 | Provention Bio Announces the Grant of Inducement Awards | RED BANK, N.J., Jan. 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company gran... |
| 20.12.2021 | Provention Bio Announces Leadership Team Expansion | RED BANK, N.J., Dec. 20, 2021 /PRNewswire/ -- December 20, 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced t... |
| 02.12.2021 | Provention Bio Announces the Grant of Inducement Awards | RED BANK, N.J., Dec. 2, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company gran... |
| 04.11.2021 | Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update | RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the third quarter ended Sep... |
| 04.11.2021 | Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer | RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Thierry Chauche will become Chief Financial... |
| 26.10.2021 | Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 | RED BANK, N.J., Oct. 26, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive interim results from PROVENT (PROtocol... |
Show more